Site‐specific survival rates for cancer of unknown primary according to location of metastases
Authors:
Open Access
- 12 December 2012
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 133 (1) , 182-189
Abstract
Cancer of unknown primary (CUP) is diagnosed at the metastatic stage and despite extensive diagnostic work‐up the primary tumor often remains unidentified. Limited population‐based survival data are available for metastatic location and none are available that link the location with the cause of death, which might give clues about the tissue‐of‐origin. A total of 9,306 CUP patients with extranodal metastases of adenocarcinoma and undifferentiated histology were identified from the Swedish Cancer Registry. Hazard ratios (HRs), mean survival times and Kaplan–Meier survival curves were provided according to CUP location at diagnosis and cause of death. The median survival was shortest (2 months) for patients with liver and longest (5 months) for those with nervous system metastases. Lung cancer was the most common cause of death in patients with CUP metastasis in the respiratory system, nervous system, bone and skin, with a median survival of 3 months. Patients with peritoneal/retroperitoneal and pelvical metastasis died not only of ovarian cancer, with a favorable median survival of 8 months, but also of pancreatic and colorectal cancers. Patients with pancreatic, liver, biliary and colorectal cancers with liver metastasis succumbed quickly. The data show that the location of metastases predicts site‐specific cancer deaths which in turn may point to the hidden primary tumor. The results should facilitate the management of CUP in proposing that the diagnostic arsenal should target the lungs when metastases are diagnosed in the respiratory or nervous system, bone or skin; ovarian tumors should be suspected after diagnosis of pelvical metastases.Keywords
This publication has 28 references indexed in Scilit:
- Cancers of unknown primary origin: current perspectives and future therapeutic strategiesJournal of Translational Medicine, 2012
- Power and limits of modern cancer diagnostics: cancer of unknown primaryAnnals of Oncology, 2011
- Subsequent cancers in patients diagnosed with cancer of unknown primary (CUP): etiological insights?Annals of Oncology, 2011
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung CancerNew England Journal of Medicine, 2010
- Senescence in tumours: evidence from mice and humansNature Reviews Cancer, 2010
- Personalized Medicine and Inhibition ofEGFRSignaling in Lung CancerNew England Journal of Medicine, 2009
- Cancer metastasis networks and the prediction of progression patternsBritish Journal of Cancer, 2009
- Population-based study of dying in hospital in six European countriesPalliative Medicine, 2008
- New Technologies for Human Cancer ImagingJournal of Clinical Oncology, 2008
- Epidemiology of unknown primary tumours; incidence and population-based survival of 1285 patients in Southeast Netherlands, 1984–1992European Journal of Cancer, 2002